Eli Lilly's new diabetes drug continues to show promise as an obesity treatment

Eli Lilly continues to work on commercializing its strong innovation pipeline, which is a key reason the CNBC Investing Club owns the stock.

Eli Lilly's new diabetes drug continues to show promise as an obesity treatment

The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.

Mike Blake | Reuters